Morphic to Present at the Jefferies 2019 London Healthcare Conference
November 18, 2019 16:15 ET
|
Morphic Therapeutic
WALTHAM, Mass., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces Corporate Highlights and Third Quarter 2019 Financial Results
November 12, 2019 16:24 ET
|
Morphic Therapeutic
MORF-720, αvβ6-targeted oral integrin inhibitor IND now anticipated in the second half of 2020α4β7-targeted oral integrin inhibitor candidate for IBD on track for IND by mid-2020Morphic ends third...
Morphic to Present at the Wells Fargo Securities 2019 Healthcare Conference
August 30, 2019 13:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces Corporate Highlights and Second Quarter 2019 Financial Results
August 12, 2019 06:30 ET
|
Morphic Therapeutic
- Successful IPO provides more than $100 million in gross proceeds to advance leading oral integrin development pipeline and MInT discovery platform - Company remains on track to file INDs for its...